Nanobiotix S.A.
NBTX
$51.50
-$3.57-6.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 360.45% | 57.17% | -79.54% | -107.83% | -138.66% |
| Total Other Revenue | -30.58% | -41.63% | -49.48% | -39.51% | -28.15% |
| Total Revenue | 562.47% | 27.44% | -75.28% | -97.24% | -119.91% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 562.47% | 27.44% | -75.28% | -97.24% | -119.91% |
| SG&A Expenses | 3.25% | -0.98% | -3.95% | -6.77% | -6.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.08% | -21.26% | -15.77% | -8.80% | 1.05% |
| Operating Income | 82.73% | 39.69% | -96.58% | -139.38% | -182.07% |
| Income Before Tax | 62.57% | 24.85% | -55.94% | -63.61% | -72.05% |
| Income Tax Expenses | -97.16% | -109.28% | -114.13% | -83.44% | -15.94% |
| Earnings from Continuing Operations | 62.62% | 25.15% | -54.61% | -62.85% | -71.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.62% | 25.15% | -54.61% | -62.85% | -71.79% |
| EBIT | 82.73% | 39.69% | -96.58% | -139.38% | -182.07% |
| EBITDA | 83.05% | 38.34% | -110.80% | -155.08% | -199.07% |
| EPS Basic | 63.19% | 27.49% | -43.07% | -34.99% | -30.94% |
| Normalized Basic EPS | 65.25% | 23.99% | -79.12% | -66.60% | -60.49% |
| EPS Diluted | 63.08% | 27.55% | -42.18% | -34.33% | -30.40% |
| Normalized Diluted EPS | 65.25% | 23.99% | -79.12% | -66.60% | -60.49% |
| Average Basic Shares Outstanding | 1.17% | 5.54% | 10.33% | 18.50% | 27.99% |
| Average Diluted Shares Outstanding | 1.17% | 5.54% | 10.33% | 18.50% | 27.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |